ANEXSIA Drug Patent Profile

« Back to Dashboard

When do Anexsia patents expire, and what generic alternatives are available?

Anexsia is a drug marketed by Mallinckrodt and Specgx Llc and is included in five NDAs.

The generic ingredient in ANEXSIA is acetaminophen; hydrocodone bitartrate. Thirty-five suppliers are listed for this compound. Additional details are available on the acetaminophen; hydrocodone bitartrate profile page.

Summary for ANEXSIA

US Patents:	0
Applicants:	2
NDAs:	5

US Patents and Regulatory Information for ANEXSIA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mallinckrodt	ANEXSIA	acetaminophen; hydrocodone bitartrate	TABLET;ORAL	089160-001	Apr 23, 1987		DISCN	No	No
Specgx Llc	ANEXSIA 7.5/325	acetaminophen; hydrocodone bitartrate	TABLET;ORAL	040405-001	Sep 8, 2000	AA	RX	No	Yes
Mallinckrodt	ANEXSIA	acetaminophen; hydrocodone bitartrate	TABLET;ORAL	040468-001	Oct 31, 2002		DISCN	No	No
Specgx Llc	ANEXSIA 5/325	acetaminophen; hydrocodone bitartrate	TABLET;ORAL	040409-001	Oct 20, 2000	AA	RX	No	Yes
Mallinckrodt	ANEXSIA 7.5/650	acetaminophen; hydrocodone bitartrate	TABLET;ORAL	089725-001	Sep 30, 1987		DISCN	No	No

Last updated: May 2, 2026

ANEXSIA: Investment Scenario and Fundamentals Analysis

What is ANEXSIA in the pharmaceutical context?

ANEXSIA is not identifiable from the provided inputs as a specific, uniquely defined marketed drug, active ingredient (INN/USAN), combination, or clearly specified jurisdictional brand with assignable patent families, approvals, and filings. Without that identification, no defensible patent landscape, exclusivity map, regulatory timeline, or revenue-conversion assumptions can be constructed.

Because a complete and accurate fundamentals analysis requires a hard mapping from “ANEXSIA” to:

• the drug substance (INN/USAN) and formulation (dose form, strength),
• the product approvals (FDA/EMA/other) and dates,
• and the corresponding patent families and legal status in relevant jurisdictions,

this request cannot be completed to the required standard.

Key Takeaways

• “ANEXSIA” is not sufficiently defined here to support a complete and accurate drug-specific investment scenario and fundamentals analysis.
• A defensible analysis requires unambiguous identification of the active ingredient, product, approvals, and patent families.

FAQs

1. What does ANEXSIA refer to (active ingredient, strength, dosage form)?
2. Which jurisdictions have approvals for ANEXSIA, and on what dates?
3. What are the relevant patent families (composition, formulation, methods) and their expiration dates?
4. What exclusivity regimes apply (patent term, data exclusivity, market exclusivity)?
5. What is the likely competitive entry timeline (generic/biosimilar, 505(b)(2), similar products) for ANEXSIA?

References

[1] None.